Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients

SAN DIEGO, Sept. 28, 2016 /PRNewswire/ -- Dermata Therapeutics, LLC, a biotechnology company focused on developing innovative medical dermatology products for dermatologists and their patients, today announces positive findings from their 28-day Phase 1 Pharmacokinetic Study in Acne Rosacea patients with their lead compound, DMT210.  The results from the Phase 1 study show that DMT210 has minimal systemic exposure, an acceptable safety profile and appears well tolerated by patients, with most reported local skin reactions as mild.  

Dermata Therapeutics, LLC

Dermata also collected efficacy data, producing meaningful results, by measuring the four main clinical endpoints for rosacea: reduction in lesion counts, investigator global assessment in rosacea, clinician's assessment of erythema, and patient's severity assessment of erythema.  These results are consistent with the findings of their non-clinical data, which indicated DMT210 may be effective to treat both the erythema and inflammation (papules and pustules) associated with rosacea.

"The safety results are supported with the findings from our pre-clinical data that DMT210 has a favorable safety profile, which remains extremely important to patients and dermatologists for dermal products," states Gerald Proehl, President and CEO of Dermata.  "We are also very excited to see that DMT210 reduced erythema and lesion counts in only a 28-day study, giving us further confidence that we will see even greater reductions in our 90-day study."  

With the completion of this study, Dermata plans to move into two Phase 2 studies in Acne Rosacea and Atopic Dermatitis, both expected to start later this year.

About Dermata: Dermata is a development-stage biotechnology company focused on making major advancements in the treatment of serious diseases treated by dermatologists. Dermata has a team of experienced individuals who are currently focused on progressing four programs for the treatment of acne rosacea, acne vulgaris, atopic dermatitis and ocular rosacea.  To learn more about Dermata and its pipeline of treatments, please visit


Dermata Contact

Gerald Proehl

President and CEO


Logo -


To view the original version on PR Newswire, visit:

SOURCE Dermata Therapeutics, LLC